Ibrutinib (PCI-32765)

For research use only. Not for use in humans.

目录号：S2680 中文名称：依鲁替尼

Ibrutinib (PCI-32765) Chemical Structure

CAS No. 936563-96-1

Ibrutinib (PCI-32765)是一种有效的，高选择性的Brutons tyrosine kinase (Btk)抑制剂，无细胞试验中IC50为0.5 nM，对Bmx， CSK， FGR， BRK及HCK适度有效，对EGFR， Yes， ErbB2， JAK3等作用效果较弱。Ibrutinib 可作为Btk配体用于合成包括P13I在内的一系列PROTAC。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 2226.41 现货
RMB 1392.54 现货
RMB 7922.62 现货
RMB 20229.3 现货
有超大折扣
大剂量询单有大折扣!
今日订购，明日送达 全国免运费 分装免费
全国免费电话：400-668-6834   |   Email：info@selleck.cn

客户使用Selleck生产的Ibrutinib (PCI-32765)发表文献476篇：

产品安全说明书

Target Protein Ligand抑制剂选择性比较

生物活性

产品描述 Ibrutinib (PCI-32765)是一种有效的，高选择性的Brutons tyrosine kinase (Btk)抑制剂，无细胞试验中IC50为0.5 nM，对Bmx， CSK， FGR， BRK及HCK适度有效，对EGFR， Yes， ErbB2， JAK3等作用效果较弱。Ibrutinib 可作为Btk配体用于合成包括P13I在内的一系列PROTAC。
靶点
BTK [1]
(Cell-free assay)		 BLK [1]
(Cell-free assay)		 Bmx [1]
(Cell-free assay)		 CSK [1]
(Cell-free assay)		 FGR [1]
(Cell-free assay)
0.5 nM 0.5 nM 0.8 nM 2.3 nM 2.3 nM
体外研究

Ibrutinib有效可逆且选择性抑制Btk酶活性。Ibrutinib作用于 BCR 通路激活的 DOHH2细胞系, 抑制Btk自磷酸化, Btk's 生理底物 PLCγ磷酸化, 和更远一点的下游激酶ERK的磷酸化，IC50分别为11 nM, 29 nM 和 13 nM。[1] Ibrutinib作用于慢性淋巴细胞白血病 (CLL) 细胞，诱导细胞毒性，这种作用存在剂量和时间依赖性。此外, Ibrutinib诱导 caspase依赖性细胞死亡通路激活，且在TLR信号后，抑制CLL细胞增殖能力。[2] 最新研究显示Ibrutinib抑制 BCR激活的原代 B细胞增殖,IC50 为8 nM，且抑制 原代单核细胞中TNFα, IL-1β 和 IL-6产量， IC50 分别为2.6 nM, 0.5 nM, 和 3.9 nM。 [3]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human Rec1 cells MULGeY5kfGmxbjDhd5NigQ>? MorJNk42KM7:TR?= M4XCSVYhcA>? Ml;XTY5pcWKrdHnvckBw\iCOeX6gdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIGLlZ|Eh[2WubIOgZZQhOi53IIXNJIlv[3WkYYTl[EBnd3JiNjDodpMh[nliV3XzeIVzdiCkbH;0eIlv\yCvZYToc4Q> MmjPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MkK4O|coRjJ3MkKyPFc4RC:jPh?=
human WSU-NHL cells M3XMXmN6fG:2b4jpZ:Kh[XO|YYm= NGLqTY04OiCq MVjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDXV3UuVkiOIHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIx2dWmwZYPj[Y51KGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwMEmg{txO NIDDXW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
human SU-DHL6 cells M2PNeWN6fG:2b4jpZ:Kh[XO|YYm= Mo[4O|IhcA>? NVvneW5TS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW1VvRFjMOkBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCudX3pcoV{[2WwdDDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlU5KM7:TT6= M1HHXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUG1NlkyLz5{NEmxOVI6OTxxYU6=
human DOHH2 cells M3PrZ2N6fG:2b4jpZ:Kh[XO|YYm= MUG3NkBp MVjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEU2hJOiClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDseY1qdmW|Y3XueEBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjRzIN88UU4> NWDLVGd{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
Sf9 cells MnXNSpVv[3Srb36gZZN{[Xl? MUixJIg> M3;4OGlvcGmkaYTpc44hd2ZiTGnOMWEh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDh[pRmeiB4MDDtbY5{KGK7IGTSMWZTTVRiQYPzZZktKEmFNUC9NE4zKM7:TT6= M1XYSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUW4OVQ4Lz5{MUm1PFU1PzxxYU6=
human Ramos cells NI\JeItHfW6ldHnvckBie3OjeR?= NXj5TlZSOSCq MnG2TY5pcWKrdHnvckBw\iCEdHugbY4hcHWvYX6gVoFud3NiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBRVENvZ3HtcYEzKHCqb4PwbI9zgWyjdHnvckBifCCWeYKxNlE4KGGodHXyJFEhcHJiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{NCCLQ{WwQVE1KG6PLh?= NIO0VWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
human Pfeiffer cells NHzkTYRHfW6ldHnvckBie3OjeR?= MVW3NkBp NYDQOYNVS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWG[naX\m[ZIh[2WubIOgZZN{\XO|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO|IhcHK|IHL5JGNmdGyWaYTldk1IdG9ibIXtbY5me2OnboSgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NkBvVS5? MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
Sf9 cells NYHLO4p4TnWwY4Tpc44h[XO|YYm= M4HtelEhcA>? M3HFbGlvcGmkaYTpc44hd2ZiaIXtZY4h\nWubD3s[Y5ofGhiQmTLJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNidYPpcochTkGPLWPyZ5Rq\GVicHXweIll\SCjczDzeYJ{fHKjdHWgZYZ1\XJiNkCgcYlveyCkeTDUVk1HWkWWIFHzd4F697zOIFnDOVA:OC53IH7NMi=> NV\mdItURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OVg2PDdpPkKxPVU5PTR5PD;hQi=>
Sf9 insect cells MnHVSpVv[3Srb36gZZN{[Xl? MVq2NEBucW6| NFTKWFlKSzVyIE2gNE4xODB|IN88US=> MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF2NkGzOkc,OjlzNE[xN|Y9N2F-
sf9 cells NUf1Wm5STnWwY4Tpc44h[XO|YYm= NYezbZZIUUN3MDC9JFAvODByMzFOwG0> MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NEezOkc,Ojd7OUS3N|Y9N2F-
Sf9 insect cells MkTySpVv[3Srb36gZZN{[Xl? M3\vUFYxKG2rboO= Ml70TWM2OCB;IECuNFAxOzRizszN MljEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUKxO|UoRjJ5OUGyNVc2RC:jPh?=
Sf9 insect cells NWLF[JpITnWwY4Tpc44h[XO|YYm= M33ve|YxKG2rboO= NGi4cFFKSzVyIE2gNE4xODB|NDFOwG0> M1jZOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEOyPVQ3Lz5{OESzNlk1PjxxYU6=
Sf9 insect cells MmP6SpVv[3Srb36gZZN{[Xl? NYq3epFrPjBibXnudy=> MnTDTWM2OCB;IECuNFAxOzRizszN M4nZbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUW2NFM4Lz5{N{m1OlA{PzxxYU6=
Sf9 cells NGXGTGlHfW6ldHnvckBie3OjeR?= NY\aV25CPjBibXnudy=> MYLJR|UxKD1iMD6wNFA1KM7:TR?= NHLYSYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MECwOlE1Oyd-M{CwNFYyPDN:L3G+
Sf9 cells NELoVVhHfW6ldHnvckBie3OjeR?= MmPXOlAhdWmwcx?= NXq0XGVVUUN3MDC9JFAvODByNTFOwG0> NWXuO3BRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OVg2PDdpPkKxPVU5PTR5PD;hQi=>
Ramos cells MmPBSpVv[3Srb36gZZN{[Xl? M{L0TFEhcA>? MlH4TWM2OCB;IECuNFAxPSEQvF2= MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MEK2NUc,Ojh{OECyOlE9N2F-
Sf9 cells Mn7RSpVv[3Srb36gZZN{[Xl? NILw[pk3OCCvaX7z M3fNVWlEPTBiPTCwMlAxOSEQvF2= NWrq[pIzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwO|c3ODhpPkOwNFc4PjB6PD;hQi=>
Pfeiffer cells M{XhcWN6fG:2b4jpZ4l1gSCjc4PhfS=> NGPaUG04OiCq MkTlS2k2OCB;IECuNFAzKM7:TR?= MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
B cells MlO2SpVv[3Srb36gZZN{[Xl? NWm1R2ZNOSCq M{TVTWlEPTBiPTCwMlAxPDZizszN MlG0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{OUC5PFgoRjNyMkmwPVg5RC:jPh?=
Sf9 insect cells M1j2eGZ2dmO2aX;uJIF{e2G7 MljHNkB1dyB4MDDtbY5{ MoC0T4khRSByLkCwOFgh|ryP M{Xw[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
Ramos cells NYjubm06TnWwY4Tpc44h[XO|YYm= NGDWSZcyKGh? Mn3JTWM2OCB;IECuNFA4PSEQvF2= NVn0[WNRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
Sf9 insect cells MWfGeY5kfGmxbjDhd5NigQ>? MVi2NEBucW6| NIi1N4NKSzVyIE2gNE4xODhizszN MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
TMD8 cells MkPvRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M4D5e|czKGh? MX3JR|UxKD1iMD6wNUDPxE1? Ml25QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5MUWwNlMoRjJ7N{G1NFI{RC:jPh?=
CD19+ B cells NETIS3NHfW6ldHnvckBie3OjeR?= M{PIPVEhcA>? M1:zZ2lEPTBiPTCwMlAyOiEQvF2= NFf5UVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS1O|k5Oid-Mkm0OVc6QDJ:L3G+
Sf9 insect cells MlrKSpVv[3Srb36gZZN{[Xl? MkH3OlAhdWmwcx?= MmTkTWM2OCB;IECuNFEzKM7:TR?= MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
Ramos cells MYLGeY5kfGmxbjDhd5NigQ>? NHPjbncyKGh? MX7JR|UxKD1iMD6wNVQh|ryP NGToeHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
Sf9 insect cells MUjGeY5kfGmxbjDhd5NigQ>? NGfpb2QyKGh? NGCxOGhKSzVyIE2gNE4xOTR2IN88US=> MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTdzNUCyN{c,Ojl5MUWwNlM9N2F-
Sf9 insect cells NUPzRVFDTnWwY4Tpc44h[XO|YYm= MnrROlAhdWmwcx?= NWnEUXJtUUN3MDC9JFAvODF4MTFOwG0> MkXCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzNE[xN|YoRjJ7MUS2NVM3RC:jPh?=
HCC827 cells NFmzOHpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= Ml\iO|IhcA>? NGfhUYlKSzVyIE2gNE4xOzlizszN Mnr4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5M{S1PFEoRjJ6N{O0OVgyRC:jPh?=
PC9 cells NHu0XGJHfW6ldHnvckBie3OjeR?= MX[3NkBp MXfHTVUxKD1iMD6wOUDPxE1? NGS0UlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
Sf9 cells NIDtZnJHfW6ldHnvckBie3OjeR?= MX62NEBucW6| MoPNTWM2OCB;IECuNUDPxE1? MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODByNkG0N{c,OzByME[xOFM9N2F-
H3255 cells MkH5SpVv[3Srb36gZZN{[Xl? Mn;nO|IhcA>? M2Lqe2dKPTBiPTCwMlEyKM7:TR?= MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
BaF3 cells NFPM[mJHfW6ldHnvckBie3OjeR?= M3jjPVczKGh? M1XRU2dKPTBiPTCwMlEzKM7:TR?= NWT3[VI1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2N|A2PTNpPkK2OlMxPTV|PD;hQi=>
BAF3 cells M3f6S2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MVq3NkBp M{\mZ2dKPTBiPTCwMlEzKM7:TR?= MmHDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
Sf9 insect cells NFe1c5pHfW6ldHnvckBie3OjeR?= M2q4O|YxKG2rboO= NIDWVIdKSzVyIE2gNE4yOjNizszN NX7rcYd2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N|E2PTl5PD;hQi=>
Sf9 insect cells M4K3NmZ2dmO2aX;uJIF{e2G7 MWG2NEBucW6| Ml3ITWM2OCB;IECuNVQ3KM7:TR?= NHnpbXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
BAF3 cells M3:1SWZ2dmO2aX;uJIF{e2G7 MkTaO|IhcA>? MmjzS2k2OCB;IECuNVYh|ryP M2n3SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
Sf9 cells NYHiSnI2TnWwY4Tpc44h[XO|YYm= MVq2NEBucW6| NYnGOnk{UUN3MDC9JFAvOiEQvF2= MonNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NUi1OFcoRjJzOUW4OVQ4RC:jPh?=
MV411 cells MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV30dJM6T0l3MDC9JFAvOjVizszN MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
MV4-11 cells NH[0cJZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= MnXmO|IhcA>? NGnOTWpIUTVyIE2gNE4{OyEQvF2= NXWycZBxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2N|A2PTNpPkK2OlMxPTV|PD;hQi=>
MV4-11 cells MYTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NWj3bphrPzJiaB?= MnPrS2k2OCB;IECuN|Mh|ryP NYPs[4VlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ|PD;hQi=>
DOHH2 cells NHe5TIJEgXSxdH;4bYNqfHliYYPzZZk> NXPpb5NyPzJiaB?= MlriS2k2OCB;IECuOFEh|ryP NHvJT4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
HCC827 cells MVvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MXu5OkBp NIPONZlGSzVyIE2gNE41PSEQvF2= NIrVT|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N|U4PSd-Mki4OVM2PzV:L3G+
SU-DHL6 cells NFjDemZEgXSxdH;4bYNqfHliYYPzZZk> M3HXd|czKGh? NWPQc|d1T0l3MDC9JFAvPThizszN NXS2NppURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
M07e cells NEjMTWRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXzHTVUxKD1iMD61PUDPxE1? NIXtOJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
NCI-H1975 cells NXTSTVZySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MVm5OkBp NFXUcYZGSzVyIE2gNE43PCEQvF2= NXXDUm17RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVM2PzVpPkK4PFU{PTd3PD;hQi=>
SU-DHL-2 cells MlHjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{LhT2dKPTBiPTCwMlY1KM7:TR?= MonwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
HEK293T cells MX7GeY5kfGmxbjDhd5NigQ>? NV;NTHd1OSCq MUnJR|UxKD1iMD65JO69VQ>? MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MEK2NUc,Ojh{OECyOlE9N2F-
Ramos cells MV;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MVO3NkBp MUPJR|UxKD1iMD65NkDPxE1? M1HVbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{G1NFI{Lz5{OUexOVAzOzxxYU6=
BA/F3 cells MnjuRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? MnvWO|IhcA>? M1;TVGlEPTBiPTCxJO69VQ>? M2nSbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkW4OVIyLz5{NkK1PFUzOTxxYU6=
WSU-NHL cells MXjDfZRwfG:6aXPpeJkh[XO|YYm= NYr4dJdCPzJiaB?= NVi2V4Z2T0l3MDC9JFEvODlizszN NWPIW5piRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
NCI-H1975 cells MYPGeY5kfGmxbjDhd5NigQ>? MoPhO|IhcA>? MmraS2k2OCB;IEGuNkDPxE1? NFq1NlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
NCI-H1975 cells M3zkRWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NFiyN3U4OiCq MUjJR|UxKD1iMT6yO{DPxE1? Mor0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5M{S1PFEoRjJ6N{O0OVgyRC:jPh?=
Raji cells MnjnRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M{XkTVQ5KGh? MYDJR|UxKD1iMT60PUDPxE1? NInIOFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW2O|I6PSd-Mkm1OlczQTV:L3G+
Pfeiffer cells MlT4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkTNS2k2OCB;IEGuOkDPxE1? M2\rWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
A431 cells MlXERY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M{PGbFk3KGh? M2DERWVEPTBiPTCyMlM5KM7:TR?= NEC5OGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N|U4PSd-Mki4OVM2PzV:L3G+
BAF3 cells M4HrWWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MonUO|IhcA>? MUjHTVUxKD1iMj61JO69VQ>? MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
U937 cells NUjoOVJbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NF[4UXZIUTVyIE2gNk46KM7:TR?= M{DQOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
NB4 cells M4X6Vmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEPBXnBIUTVyIE2gN{DPxE1? NYXZ[WE4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N|E2PTl5PD;hQi=>
Ramos cells NWj2[GJMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWX5VIRQT0l3MDC9JFMvPCEQvF2= MorFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
SKM1 cells M{e2W2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYTHTVUxKD1iMz62JO69VQ>? NVi2VmVCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N|E2PTl5PD;hQi=>
U2932 cells M{XEOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWrHTVUxKD1iND60JO69VQ>? MkXSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
Ramos cells MVLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MWK3NkBp NUizV4VNUUN3MDC9JFUvOTRizszN MlzJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByME[xOFMoRjNyMEC2NVQ{RC:jPh?=
Ramos cells MUfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MkPoOFghcA>? M1z2TGlEPTBiPTC1MlE1KM7:TR?= M1L2VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUW2NFM4Lz5{N{m1OlA{PzxxYU6=
Ramos cells NUKxbYVwSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MoO5OFghcA>? M4iyO2lEPTBiPTC1Mlg5KM7:TR?= MnjtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2M{K5OFYoRjJ6NEOyPVQ3RC:jPh?=
Ramos cells Mlq0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M17BV|czKGh? MkLnTWM2OCB;IE[uOlIh|ryP NYjyRmZPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxOFYyOzZpPkK5NVQ3OTN4PD;hQi=>
K562 cells MnuzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? MoDXOFghcA>? MnXtTWM2OCB;IEeuOUDPxE1? MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB5N{[wPEc,OzByN{e2NFg9N2F-
HL60 cells NFXq[HlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NYPtPJhiPDhiaB?= M3zYfWlEPTBiPTC4JO69VQ>? MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB5N{[wPEc,OzByN{e2NFg9N2F-
Ramos cells NHjQZmtCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= M1Xyc|Q5KGh? MnnHTWM2OCB;IEiuNVEh|ryP M{jpPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUm0O|M3Lz5{N{m5OFc{PjxxYU6=
Ramos cells NXTxc3BbSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MVO0PEBp NUOwNW1HUUN3MDC9JFgvOjZizszN MoPuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3NkeyPVUoRjJ7NU[3Nlk2RC:jPh?=
OCI-AML3 cells NVrT[oNxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NH\vcHFIUTVyIE2gPU4zKM7:TR?= MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh|MUW1PVc9N2F-
BAF3 cells NF3QWWNEgXSxdH;4bYNqfHliYYPzZZk> NFv6eIY4OiCq Mm\uS2k2OCB;IEGwJO69VQ>? Ml73QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4M{C1OVMoRjJ4NkOwOVU{RC:jPh?=
BAF3 cells M1juZ2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NHrORWY4OiCq NYLxS2pCT0l3MDC9JFExKM7:TR?= MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
BAF3 cells MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYX3c5RZPzJiaB?= NFTwO4tIUTVyIE2gNVAh|ryP MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
NAMALWA cells MWHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NGXHSGQ4OiCq NIq4NG5KSzVyIE2gNVAvPDVizszN MojTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzNE[xN|YoRjJ7MUS2NVM3RC:jPh?=
Ramos cells MXXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MVe0PEBp MnOyTWM2OCB;IEGyMlYh|ryP MljKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUKxO|UoRjJ5OUGyNVc2RC:jPh?=
Raji cells MUnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NH;POoU1QCCq NF3CTVNKSzVyIE2gNVQvOiEQvF2= MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB5N{[wPEc,OzByN{e2NFg9N2F-
Raji cells Mm\ORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M4P3OlQ5KGh? MofVTWM2OCB;IEG1MlIh|ryP M3[4V|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUm0O|M3Lz5{N{m5OFc{PjxxYU6=
MIAPaCa2 cells M4W3eWN6fG:2b4jpZ4l1gSCjc4PhfS=> NGDyO5I{KGSjeYO= NGnhUphKSzVyIE2gNVYvPiEQvF2= NYjD[29GRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewO|czOjhpPkK3NFc4OjJ6PD;hQi=>
HeLa cells NHv3eoREgXSxdH;4bYNqfHliYYPzZZk> Mlm1N{Bl[Xm| NFX3e|hKSzVyIE2gNVYvQCEQvF2= NEHqZ3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C3O|IzQCd-MkewO|czOjh:L3G+
Raji cells MYrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NIna[Ww1QCCq NU\3PZk4UUN3MDC9JFE6NjNizszN MnHpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUKxO|UoRjJ5OUGyNVc2RC:jPh?=
Raji cells M3LBcGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MkH5OFghcA>? Ml;oTWM2OCB;IEG5MlMh|ryP MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR|Mkm0Okc,Ojh2M{K5OFY9N2F-
Raji cells NWj4UYF6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NFfVVZk4OiCq NWf3N2tXUUN3MDC9JFE6NjVizszN NITVelM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MECwOlE1Oyd-M{CwNFYyPDN:L3G+
Raji cells NEfmNGhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= Mmf4OFghcA>? NFL6UWhKSzVyIE2gNVkvPSEQvF2= M{jlSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUW2NFM4Lz5{N{m1OlA{PzxxYU6=
NAMALWA cells M2\oe2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MVG3NkBp NYrMPGQ3UUN3MDC9JFE6NjZizszN Mny3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByME[xOFMoRjNyMEC2NVQ{RC:jPh?=
A2780 cells M2nFTGN6fG:2b4jpZ4l1gSCjc4PhfS=> Mn:xN{Bl[Xm| NHW5bFFGSzVyIE2gNlAvOSEQvF2= MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB5N{KyPEc,OjdyN{eyNlg9N2F-
Raji cells NULs[WtkSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MU[3NkBp M1nDdGlEPTBiPTCyNE45QCEQvF2= MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF2NkGzOkc,OjlzNE[xN|Y9N2F-
A549 cells MkLvRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NGT2XnQ4OiCq NFPr[5pKSzVyIE2gNlEvPzlizszN NFv4U3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEezOFU5OSd-Mki3N|Q2QDF:L3G+
SW480 cells MYTDfZRwfG:6aXPpeJkh[XO|YYm= MorhN{Bl[Xm| NICwSFNKSzVyIE2gNlUvPiEQvF2= MmPBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyN{eyNlgoRjJ5MEe3NlI5RC:jPh?=
Ramos cells M2jkc2N6fG:2b4jpZ4l1gSCjc4PhfS=> MWOyOEBp MmPXTWM2OCB;IEK4Mlch|ryP MkLuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{N{S2O|UoRjJ6Mke0Olc2RC:jPh?=

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
pEGFR(Tyr1068) / EGFR; 

PubMed: 28061447     


Ibrutinib inhibitory effects on EGFRY1068 auto-phosphorylation in the HCC827 cell line at different time points by removal of drug after 4 h pretreatment.

pBTK / pPLCγ2 / pAKT / pERK / pJNK; 

PubMed: 23940282     


Mino (left panel) or Jeko1 (right panel) cells pretreated with vehicle or ibrutinib 10, 100, or 1000 nM were either stimulated with anti-IgM, CXCL12, or CXCL13 or treated with medium (Med) for 15 minutes and then immunoblotted for pBTK, pPLCγ2, pAKT, pERK, and pJNK.

28061447 23940282
Immunofluorescence
CD11b; 

PubMed: 30231870     


BV2 microglial cells were pretreated with ibrutinib (1 μM) or vehicle (1% DMSO) for 30 min, followed by treatment with LPS (1 μg/ml) or PBS for 5.5 h and immunostaining with an anti-CD11b antibody. Scale bar = 20 μm.

COX-2; 

PubMed: 30231870     


BV2 microglial cells were treated with vehicle (1% DMSO) or ibrutinib (1 μM) for 30 min, followed by PBS or LPS (1 μg/ml) for 5.5 h, and immunocytochemistry was conducted with anti-CD11b and anti-COX-2 antibodies. 

30231870
ELISA
hTNFα; 

PubMed: 26627823     


PBMs were isolated and pretreated with 1, 5, or 10 μm ibrutinib (IB) or left untreated (UT, −). Pretreated PBMs were incubated for 24 h in 96-well plates precoated without (PBS) or with 10 μg/ml whole human IgG. Cleared supernatants were collected and analyzed by ELISA for TNFα (n = 3).

IL-10; 

PubMed: 27792904     


LMP2A-negative (vector.1/.2) and -positive (express LMP2A) B cell lines were incubated in the absence or presence of increasing concentrations of Ibrutinib for 24 hours and supernatants were isolated for analysis using an IL-10 ELISA.

26627823 27792904
体内研究

Ibrutinib 作用于胶原诱导的关节炎模型，通过抑制B细胞活性，显著降低足肿胀和关节发炎等临床关节炎症状。Ibrutinib 作用于 MRL-Fas(lpr) 狼疮模型 ,降低肾疾病和自身抗体产量。[1] Ibrutinib 每天按25 mg/kg剂量作用于过继转移TCL1 的CLL小鼠模型, 产生短暂的早期淋巴细胞增多症，且延迟CLL 疾病进展。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验：

[1]
- 合并

激酶实验:

激酶, 33P-ATP, Ibrutinib, 和底物 [0.2 mg/mL 聚(EY)(4:1)]温育1小时后，使用33P 过滤结合实验测量体外激酶IC50值。
细胞实验：

[2]
- 合并
  • Cell lines: 慢性淋巴细胞白血病 (CLL) 细胞
  • Concentrations: 0.01 μM到100 μM
  • Incubation Time: 48小时
  • Method:

    进行MTT实验测定细胞毒性。细胞(CLL B 细胞或健康志愿者T 细胞或 NK细胞) 和不同浓度 Ibrutinib温育48小时。加入MTT试剂,实验板再温育20小时，然后使用溶于PBS的硫酸鱼精蛋白冲洗。加入DMSO，通过分光光度法使用Labsystems 酶标仪，在540 nm处测定吸光值。使用膜联蛋白/PI 流式细胞仪在不同时间点测量细胞活力。使用 Expo-ADC32 软件包分析数据。结果表示为总阳性细胞与对照组之比的百分数。加入100μM Z-VAD检测caspase依赖性凋亡。


    (Only for Reference)
动物实验：

[1]
- 合并
  • Animal Models: MRL-Fas(lpr) 狼疮模型和胶原诱导的关节炎模型
  • Dosages: ≤50 mg/kg
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 88 mg/mL (199.77 mM)
Water Insoluble
Ethanol '45 mg/mL warmed
体内 从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)：
5% DMSO+30% PEG 300+5% Tween 80+ddH2O
 10mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 440.5
化学式

C25H24N6O2
CAS号 936563-96-1
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量 只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量：

总分子量：g/mol

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04665115 Withdrawn Drug: Ibrutinib|Other: Quality-of-Life Assessment Asymptomatic COVID-19 Infection Laboratory-Confirmed|B-Cell Neoplasm|Chronic Lymphocytic Leukemia|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma|Symptomatic COVID-19 Infection Laboratory-Confirmed|Waldenstrom Macroglobulinemia Academic and Community Cancer Research United|National Cancer Institute (NCI) December 2021 Phase 2
NCT05105841 Recruiting Drug: Venetoclax|Drug: Ibrutinib|Drug: Obinutuzumab Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL) AbbVie November 8 2021 Phase 2
NCT04876092 Recruiting Drug: JNJ-67856633|Drug: Ibrutinib Leukemia Lymphocytic Chronic B-Cell|Lymphoma Non-Hodgkin Janssen Research & Development LLC July 28 2021 Phase 1
NCT04294641 Recruiting Drug: Ibrutinib Chronic GVHD National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) May 10 2021 Phase 2
NCT04514393 Not yet recruiting Drug: Methotrexate|Drug: Ibrutinib|Drug: Temozolomide Primary Central Nervous System Lymphoma|PCNSL|Non Hodgkin Lymphoma Huiqiang Huang|Guangdong 999 Brain Hospital|Nanfang Hospital of Southern Medical University|Xian-Janssen Pharmaceutical Ltd.|Sun Yat-sen University December 1 2020 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1：

    How to reconstitute the compound S2680 for in vivo studies?

  • 回答：

    For in vivo study, we suggest to use 5% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 10mg/ml.

Selleck产品目录册
Tags: 购买Ibrutinib (PCI-32765) | Ibrutinib (PCI-32765)供应商 | 采购Ibrutinib (PCI-32765) | Ibrutinib (PCI-32765)价格 | Ibrutinib (PCI-32765)生产 | 订购Ibrutinib (PCI-32765) | Ibrutinib (PCI-32765)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID